DSS, Inc. is a globally diversified enterprise with operations across numerous industries. In product packaging, the company specializes in manufacturing and distributing custom folding cartons, mailers, photo sleeves, and advanced three-dimensional direct mail products. It also engages in the marketing and distribution of nutritional and personal care items. Within the biotechnology and biohealth sphere, DSS makes strategic investments in and acquires companies dedicated to pioneering drug discovery, prevention, and treatment methodologies for neurological, oncological, and immune-system diseases. Furthermore, it develops innovative open-air defense systems designed to combat airborne infectious agents like tuberculosis and influenza. The firm's financial services and commercial lending activities involve acquiring equity positions in undervalued commercial banks, bank holding companies, and licensed non-banking financial institutions. Its related non-banking ventures include loan syndication, mortgage banking, trust and escrow services, banking technology solutions, loan servicing, equipment leasing, problem asset management, consulting for special purpose acquisition companies (SPACs), and advisory capital raising services. For securities and investment management, DSS offers a range of services, including managing a real estate investment trust (REIT) focused on acquiring hospitals and various acute and post-acute care facilities, with an emphasis on fostering healthy living communities. The company also develops and invests in assets within the securities trading and fund management sectors, and operates as a broker-dealer for digital assets. In the alternative energy sector, DSS provides solutions such as solar farms, solar battery storage systems, and services for residential energy generation and storage. Established in 1984, the company was formerly known as Document Security Systems, Inc. before officially changing its name to DSS, Inc. in September 2021. Its headquarters are located in West Henrietta, New York.
globenewswire.comDSS, Inc. Withdraws Registration Statementglobenewswire.comJun 9
gurufocus.comImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027gurufocus.comMay 19
globenewswire.comDSS, Inc. Reports Going Concern Audit Opinion in 2025 10-K Filingglobenewswire.comMay 8
globenewswire.comDSS, Inc. Letter to Shareholdersglobenewswire.comApr 15